Literature DB >> 6323565

Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure.

M Packer, N Medina, M Yushak.   

Abstract

The relation between pretreatment serum sodium concentration and the early and late effects of captopril was examined in 77 consecutive patients with severe chronic heart failure, in whom cardiac catheterization was performed during initiation of treatment and after 2 to 8 weeks. Two groups of patients were defined: 37 patients had hyponatremia (serum sodium less than 135 mEq/liter, group A) and 40 patients had a normal serum sodium concentration (greater than or equal to 135 mEq/liter, group B). With first doses of captopril, patients in group A showed more marked hemodynamic responses than did patients in group B (p less than 0.02). The changes in mean arterial pressure and left ventricular filling pressure seen with first doses of the drug varied linearly and inversely with the pretreatment serum sodium concentration (r = -0.58 and r = -0.53, respectively); this was likely related to the finding that, before administration of captopril, the serum sodium concentration varied linearly and inversely with the logarithm of the plasma renin activity (r = -0.78). However, the pretreatment serum sodium concentration did not predict the long-term hemodynamic or clinical responses to converting enzyme inhibition. Symptomatic hypotension occurred early in the course of therapy (within 24 hours of initiating captopril therapy) in 9 (12%) of the 77 patients; 8 of these 9 had severe hyponatremia (serum sodium less than 130 mEq/liter) and comprised 53% of the 15 patients in our study with such low serum sodium concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323565     DOI: 10.1016/s0735-1097(84)80364-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  15 in total

Review 1.  Treatment of mild congestive heart failure. The potential for new drugs to reduce the risks.

Authors:  U Ravens; M Wehr
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 2.  Cardiac effects of angiotensin converting enzyme inhibitors.

Authors:  N Sharpe
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 3.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

4.  Evaluation of the safety of enalapril in the treatment of heart failure in the very old.

Authors:  C J O'Neill; S G Bowes; C M Sullens; J P Royston; W B Hunt; M J Denham; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Lisinopril: dose-peak effect relationship in essential hypertension.

Authors:  V J Cirillo; H J Gomez; J Salonen; R Salonen; V Rissanen; J A Bolognese; R Nyberg; K Kristianson
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

Review 6.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 7.  Vasodilators. A re-evaluation of their role in heart failure.

Authors:  L W Stevenson; G Fonarow
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 8.  Hyponatremia in patients with heart failure.

Authors:  Theodosios D Filippatos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2013-09-26

9.  Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1994-10       Impact factor: 4.335

Review 10.  Pharmacokinetic optimisation of angiotensin converting enzyme (ACE) inhibitor therapy.

Authors:  M Burnier; J Biollaz
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.